Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice.

ABSTRACT: The NETTER-1, VISION, and TheraP trials proved the efficacy of repeat intravenous application of small radioligands. Application by subcutaneous, intraperitoneal, or oral routes is an important alternative and may yield comparable or favorable organ and tumor radioligand uptake. Here, we assessed organ and tumor biodistribution for various radioligand application routes in healthy mice and models of cancer expressing somatostatin receptor (SSTR), prostate-specific membrane antigen (PSMA), and fibroblast activation protein (FAP). Methods: Healthy and tumor-bearing male C57BL/6 or NOD SCID γ-mice, respectively, were administered a mean of 6.0 ± 0.5 MBq of ⁶⁸Ga-DOTATOC (RM1-SSTR allograft), 5.3 ± 0.3 MBq of ⁶⁸Ga-PSMA11 (RM1-PSMA allograft), or 4.8 ± 0.2 MBq of

SUBMITTER: Klose JM 

PROVIDER: S-EPMC9454467 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature